## Abstract The inhibition of integrin function is a major challenge in medicinal chemistry. Potent ligands are currently in different stages of clinical trials for the antiangiogenic therapy of cancer and age‐related macula degeneration (AMD). The subtype α5β1 has recently been drawn into the focu
Design of superactive and selective integrin receptor antagonists containing the RGD sequence
✍ Scribed by Horst Kessler; Beate Diefenbach; Dirk Finsinger; Armin Geyer; Marion Gurrath; Simon L. Goodman; Günter Hölzemann; Roland Haubner; Alfred Jonczyk; Gerhard Müller; Erich Graf Roedern; Jochen Wermuth
- Book ID
- 104628403
- Publisher
- Springer Netherlands
- Year
- 1995
- Tongue
- English
- Weight
- 379 KB
- Volume
- 2
- Category
- Article
- ISSN
- 1573-3149
No coin nor oath required. For personal study only.
✦ Synopsis
Integrins play a major role in cell-cell and cell-matrix interactions. The majority of the different types of integrins recognize the tripeptide sequence arginine-glycine-aspartic acid (RGD). To explore the spatial requirements of the pharmacophore for receptor selectivity and high activity, a new procedure, 'spatial screening', was used. The procedure is based on the experience that the conformation of small cyclic peptides is mainly determined by the chirality of the amino acids (and glycine or proline). For example, cyclic pentapeptides with one D and four L amino acids prefer a 13II'/~/conformation. The sequence RGDFV was shifted around this spatial I~II'/y template by synthesis of five peptides in which one of the amino acids was used in D-configuration. It turned out that cyclo(-RGDfV-) is a selective inhibitor for the %[33 integrin, which is strongly expressed in cancer cells. Systematic variations with different turn mimetics, retro-inverso structures, modified peptide bonds and sugar amino acids are discussed.
📜 SIMILAR VOLUMES
The peptide oxytocin (OT) antagonist atosiban, approved for tocolytic use in Europe (under the tradename Tractocile), represents an important new therapeutic advance for the treatment of premature labor. This paper presents some new peptide OT antagonists which offer promise as superior tocolytics.